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congenital myopathy, especially when
neonatal hypotonia with breathing
and swallowing difﬁculties is present.
This study also establishes the exis-
tence of null alleles for Nav1.4 in
humans and illustrates the differential
consequences of inheriting a hypo-
morphic loss-of-function allele versus
a complete null.
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Hypoxia, a turning point in migraine
pathogenesis?
This scientiﬁc commentary refers to
‘Migraine induced by hypoxia: an
MRI spectroscopy and angiography
study’, by Arngrim et al.
(doi:10.1093/brain/awv359).
Experimental models of human dis-
eases are vital for pathophysiological
and therapeutic research. In migraine,
animal models have contributed greatly
to better understanding of causal
mechanisms and to the development
of novel therapies, but they do not
allow comprehensive analysis of the
entire clinical phenotype. Human
models are more suitable for this pur-
pose, particularly because there are
no insurmountable ethical barriers to
inducing migraine attacks as they pro-
duce no sequelae and are treatable.
The nitroglycerin test is the best stu-
died human model for inducing attacks
in migraine patients, although various
other compounds have a similar effect
(Olesen, 2008). The sensitivity of the
nitroglycerin test is up to 80% in
migraine without aura. However,
nitroglycerin only rarely induces a
migrainous headache in patients with
migraine with aura and almost never
an aura (Sances et al., 2004). A
human model for the induction of
migraine with aura attacks is thus
still missing. In this issue of Brain,
Arngrim and co-workers demonstrate
that exposure to hypoxia may be one
such model (Arngrim et al., 2016).
There are several reasons why nor-
mobaric hypoxia might be suitable.
First, there is evidence that migraine
(with aura) attacks may be triggered
when blood oxygen saturation
decreases. High-altitude headache
occurs frequently with ascent above
2500 m, has at least some migrainous
features and is more prevalent in
mountaineers with a history of
migraine (ICHD-3b, code 10.1.1
2013). Moreover, sleep apnoea-
induced migraine attacks improve
after bariatric surgery (Kallweit
et al., 2011). Second, it has been
known for more than two decades
from studies in vitro and in vivo
that hypoxia can induce spreading
depression (Somjen et al., 1992), the
most likely cortico-subcortical genera-
tor of the migrainous aura, thought to
be favoured by increased brain gluta-
mate levels. Third, mitochondrial
energy metabolism may be deﬁcient
in migraine with and without aura
between attacks, a frequently neg-
lected facet of migraine pathophysiol-
ogy that could sensitize migraineurs
to hypoxia (Paemeleire and
Schoenen, 2013). That metabolic fail-
ure might play a crucial role in
migraine was hypothesized by Amery
in 1982, before the ﬁrst experimental
data supporting the hypothesis were
obtained by studies using 31P mag-
netic resonance spectroscopy (MRS).
The most recent of these used
improved methodology and found
that ATP is decreased by 16%
and phosporylation potential by
39% in migraine patients between
attacks (Reyngoudt et al., 2011).
Interestingly, experimental mitochon-
drial poisoning also induces cortical
spreading depression and facilitates
hypoxia-induced spreading depression
in rat hippocampal slices. Fourth, the
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tion is mediated in part by nitric
oxide (Van Mil et al., 2002), to
which migraine patients are thought
to be hypersensitive (Olesen, 2008).
There is thus a convincing rationale
for testing the effects of hypoxia in
migraine with aura, as in the sham-
controlled, blinded study by Arngrim
and co-workers.
Arngrim et al. explored whether 3 h
of breathing air containing 11% O2,
which is equivalent to 4700 m alti-
tude and which reduced capillary
oxygen saturation (SpO2) to 72%,
was able to induce attacks in 15
patients suffering exclusively from
migraine with aura and in 14 healthy
volunteers. In addition, they obtained
invaluable information on possible
pathophysiological mechanisms by
determining glutamate and lactate
levels in visual cortex (1H-MRS) and
venous blood, and by measuring the
circumference of cranial arteries (3 T
high-resolution magnetic resonance
angiography). The results are highly
interesting and thought-provoking
(Fig. 1).
Is hypoxia an adequate
human model for
migraine with aura?
First, the clinical results show that 8
of 15 (53%) patients with migraine
with aura developed migraine head-
ache-like attacks during hypoxia,
compared to one after sham hypoxia
and one healthy volunteer. Headache
without typical migrainous features
occurred in 13 patients and 11 volun-
teers. Three patients (20%) reported
typical ICHD3b auras, one after
sham exposure, while seven patients
with migraine with aura and two
volunteers had ‘atypical auras’
during hypoxia, mainly blurred
vision. Using a strict deﬁnition, the
hypoxia test has a 100% speciﬁcity
for aura, the hallmark of the migraine
subtype studied here, but a low
(20%) sensitivity. For comparison,
infusion of calcitonin gene-related
peptide (CGRP) induced migraine-
like headache in 57% of a group of
patients with migraine with aura and
aura in 28% (Hansen et al., 2008),
while sublingual nitroglycerin pro-
duced headache but no aura in
13.6% of patients (Sances et al.,
2004). Sensitivity for aura increases
to 67% if ‘atypical’ auras are
included at the expense of a decrease
in speciﬁcity (86%). The precise
nature of such ‘atypical’ auras is not
certain, however, as blurred vision
and difﬁculty in ocular ﬁxation are
quite common during the whole
course of severe migraine without
aura attacks. By the same token, the
Figure 1 The links between migraine and hypoxia. Rows 1 and 2 summarize putative migraine triggers, and aspects of migraine
pathophysiology that establish a rationale for testing whether hypoxia can provoke attacks of migraine with aura. Row 3 shows possible vascular
and biochemical changes that hypoxia might induce and Row 4 the findings of Arngrim et al. The arrow labelled ‘? Yes’ refers to the possibility that
brain lactate levels may have been higher in patients who developed a migraine-like headache. The role of O2-sensing neurons and the combination
of hypoxia with visual stimulation are worthy of investigation in future studies.
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border between ‘migraine-like head-
aches’ and non-migrainous headaches
is fuzzy. This is illustrated in the
headache classiﬁcation shown in
Supplementary Table 1 of Arngrim
et al. (2016). Migraine with aura
Patient 7, for instance, was consid-
ered to have a ‘migraine-like’ attack
induced by hypoxia, although he
had no associated symptoms and a
moderate headache aggravated by
exertion, which can be tested only
after the hypoxia. By contrast,
during placebo Patients 5 and 13
had a moderate headache that
mimicked their usual migraine, but
which was nevertheless classiﬁed as
‘non-migraine-like’. More surpris-
ingly, during hypoxia, Patient 13
also developed bilateral, severe,
throbbing headache, aggravated by
movement and associated with photo-
phobia that he considered similar to
his usual attacks, but again this was
not classiﬁed as ‘migraine-like’. It is
likely that several headaches during
both hypoxia and placebo were
‘probable’ migraine without aura
attacks (ICHD3B 1.5.1) with one
missing diagnostic criterion. Finally,
patients were still included in the
study with ‘tension-type headache’
for 5 days per month. As tension-
type headaches can mimic mild
migraine without aura attacks, this
opens the door for inclusion of
patients suffering from both migraine
with and without aura, who are
highly prevalent in clinical practice,
and hence for a bias toward a
higher frequency of hypoxia-induced
migraine without aura attacks.
Schoonman et al. (2006) were the
ﬁrst to investigate the attack-inducing
effect of normobaric hypoxia in a
mixed group of eight patients with
migraine without aura and eight
patients with migraine with aura and
to compare it with that of intravenous
nitroglycerin or placebo in a double-
dummy design. They found that
hypoxia induced migraine attacks
without aura in 6 of 14 patients
(43%) who underwent the three pro-
vocations, while the incidence after
nitroglycerin was surprisingly low
(21%). Overall, three patients with
migraine with aura (37.5%) and
four patients with migraine without
aura (50%) developed a migraine
attack during hypoxia, but no aura
was reported. The lower incidence in
migraine with aura patients compared
to that seen by Arngrim et al. could
be due to the fact that the hypoxia
was less severe (SpO2 75–80%),
although on the other hand it was
of longer duration (5 h).
Are the effects of
hypoxia in migraine
with aura mediated by
metabolic or vascular
changes?
The metabolic and vascular studies
performed by Arngrim et al. failed
overall to ﬁnd a difference between
patients with migraine with aura and
controls. Intra- and extracranial
arteries dilated slightly (10–15%)
during hypoxia in both groups of sub-
jects, conﬁrming that vasodilatation
has no major role in migraine genera-
tion, and there was no correlation
with the migraine headache. Instead,
the authors suggest that patients with
migraine with aura may be supersensi-
tive to NO or other chemicals inﬂu-
enced by hypoxia, such as cyclic
guanosine monophosphate (cGMP) or
adenosine. While there are no data
available for the latter, NO supersen-
sitivity, as demonstrated for migraine
without aura in many studies with the
exception of that by Schoonman et al.,
is unlikely to be prevalent in migraine
with aura patients, who rarely develop
migraine-like headache after nitrogly-
cerin provocation (Sances et al., 2004).
Brain glutamate levels were normal
at baseline in patients with migraine
with aura and not increased after
hypoxia. This does not a priori sup-
port the ‘glutamatergic hyperexcit-
ability’ model of migraine with aura
pathophysiology, although glutamate
and glutamine may be difﬁcult to dis-
tinguish on 1H-MRS and glutamate is
undoubtedly an important factor in
cortical spreading depression.
In contrast to previous reports,
Arngrim et al. also found no abnorm-
ality of baseline lactate in visual
cortex. As expected, brain and blood
lactate levels rose during hypoxia, but
on average to a similar extent in
patients with migraine with aura
and healthy volunteers. The authors
thus conclude, and rightly so, that
these ﬁndings are not consistent with
a mitochondrial abnormality in
migraine with aura, as suggested by
the 31P MRS studies cited above. It is
worth mentioning nonetheless that
Glossary
Cortical spreading depression (CSD): A neurono-glial phenomenon initially described by Lea˜o (1944) and characterized by a brief neuronal
depolarization followed by inhibition of neuronal activity for long periods. CSD can be induced in the cerebral cortex by mechanical, chemical or
electrical triggers and is favoured by hypoxia and hypoglycaemia. There is strong evidence that CSD causes the aura symptoms in migraine.
Migraine with aura: Headache attacks preceded or accompanied by transient neurological disturbances of which the most frequent and
characteristic are scintillating scotomata (ICHD 3beta-code 1.2.1)
Nitric oxide (NO): A gaseous neuromodulator that plays a role in cerebral blood flow regulation and in nociception, in particular in the
trigeminovascular (TGV) system. NO interacts with calcitonin-gene related peptide (CGRP), a vasodilating neuropeptide that plays a seminal
role in TGV nociception. NO donors, like nitroglycerin, are able to induce a migrainous headache in the majority of migraine without aura patients
after a delay of several hours.
Phosphorylation potential: The phosphorylation potential (PP) is an index of free available energy per ATP molecule, and usually calculated from
31P magnetic resonance spectroscopy data as follows: PP = (ATP)
(ADP)(Pi)
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venous blood lactate was signiﬁcantly
increased in patients with migraine
with aura at the 1-h post-hypoxia
time point. Whether this is due to the
decreased phosphorylation potential
observed in the muscles of patients
with migraine with aura (Barbiroli
et al., 1992) remains unclear.
Moreover, Arngrim and co-workers’
data in their Fig. 2 might suggest
that patients with migraine with aura
who developed migraine-like head-
aches after hypoxia tended to have
higher brain lactate levels than those
who did not, and that the groups
were too small for this difference to
reach statistical signiﬁcance. In fact,
one can speculate that lactate may
not be the optimal marker to detect
subtle impairments of mitochondrial
energy metabolism because of its com-
plex role in neurono-glial functions
(Magistretti and Pellerin, 1999).
Future studies could use the combina-
tion of hypoxia and visual stimulation
for increased sensitivity, and/or mea-
surement of brain pH changes with
T1 MRI mapping (Heo et al., 2015).
To conclude, the study by Arngrim
et al. is important because it provides
important data about the pathophy-
siology of migraine with aura and sug-
gests that hypoxia could be a valuable
model for this subtype of migraine,
although it induces migrainous head-
ache more consistently than aura.
The results set the scene for future stu-
dies that should aim to increase the
sensitivity of the model, and also
take into account the genetic heteroge-
neity of migraine, the presence of
oxygen-sensing neurons in the CNS
(Neubauer and Sunderram, 2004)
and of meningeal TRPA1 channels
able to transduce oxidative stress and
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Inflammatory changes in very early Alzheimer’s
disease: friend, foe, or don’t know?
This scientiﬁc commentary refers to
‘Diverging longitudinal changes in
astrocytosis and amyloid PET in
autosomal-dominant Alzheimer’s dis-
ease’, by Rodriguez-Vieitez et al.
(doi:10.1093/brain/awv404).
Whilst a deﬁnitive diagnosis of spor-
adic Alzheimer’s disease still rests on
pathological conﬁrmation, the emer-
gence of biomarkers capable of reveal-
ing different aspects of pathology
in vivo has led to a paradigm shift in
how we conceptualize the disease. PET
imaging using ligands that bind ﬁbril-
lar amyloid-b or CSF measures of
amyloid-b1-42 allow for the demon-
stration of amyloid pathology in life;
MRI allows for cerebral and
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